Group structure
24 companies in 9 countries
Loading your page…
Loading your page…
24 companies in 9 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 421
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AGRASTAT | Tirofiban | Brazil | Authorised | 2010 |
| ALCACHOFRA ASPEN PHARMA | Cynara scolymus l. | Brazil | Authorised | 2009 |
| ALDOMET | Methyldopa | Brazil | Authorised | 2010 |
| ALKERAN | Melphalan | Brazil | Authorised | 2017 |
| ALKERAN10 ml / vial + 50 mg / vial · Kit, Powder For Solution, Solution | Buffer solution, Melphalan | Canada | Marketed | 1995 |
| ALKERANCompressa rivestita con film | Melphalan | Italy | Authorised | |
| ALKERAN2 mg · Tablet | Melphalan | Canada | Marketed | 1964 |
| ALKERAN 2 MG COMPRIMIDOS RECUBIERTOS CON PELICULA2 mg · Comprimido recubierto con película | Melphalan | Spain | Marketed | 2021 |
| Alkeran 2 mg, filmomhulde tablettenFilmomhulde tablet | Melphalan | Netherlands | Authorised | 1964 |
| Alkeran 50 mg Infuus, poeder en oplosmiddel voor oplossing voor infusiePoeder en oplosmiddel voor oplossing voor infusie | Melphalan | Netherlands | Authorised | 1973 |
| ALKERAN 50 MG POLVO Y DISOLVENTE PARA SOLUCION PARA PERFUSION50 mg · Polvo y disolvente para solución para perfusión | Melphalan | Spain | Authorised | 2021 |
| ARIXTRA2.5 mg / 0.5 ml · Solution | Fondaparinux | Canada | Marketed | 2002 |
| ARIXTRA | Fondaparinux | Brazil | Authorised | 2017 |
| ARIXTRA7.5 mg / 0.6 ml · Solution | Fondaparinux | Canada | Marketed | 2008 |
| ARIXTRA5 mg / 0.4 ml · Solution | Fondaparinux | Canada | Not marketed | 2008 |
| ARIXTRA10 mg / 0.8 ml · Solution | Fondaparinux | Canada | Not marketed | 2008 |
| ASPEN-DIENOGEST2 mg · Tablet | Dienogest | Canada | Marketed | 2020 |
| ASPEN-SEMAGLUTIDE1.34 mg / ml · Solution | Semaglutide | Canada | Authorised | |
| ASPEN-SEMAGLUTIDE1.34 mg / ml · Solution | Semaglutide | Canada | Authorised | |
| AZATIOPRINA ASPENCompressa rivestita con film | Azathioprine | Italy | Authorised | |
| BENESTARE | Polycarbophil calcium | Brazil | Authorised | 2021 |
| BUSULFANO ASPEN 2 MG COMPRIMIDOS RECUBIERTOS CON PELICULA2 mg · Comprimido recubierto con película | Busulfan | Spain | Marketed | 1959 |
| CALMAN | Crataegus rhipidophylla gand., Passiflora incarnata l., Salix alba l. | Brazil | Authorised | 2017 |
| CENESTIN0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.9MG **Federal Reg · Tablet | Conjugated estrogens, Conjugated synthetic a | United States | Not marketed | 1999 |
| Citanest 10 mg/ml, oplossing voor injectieOplossing voor injectie | Prilocaine | Netherlands | Authorised | 1984 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Brazil | 181 | 37 | 144 | CompaniesAll medicines |
| Canada | 67 | 65 | 2 | CompaniesAll medicines |
| Netherlands | 55 | 55 | 0 | CompaniesAll medicines |
| Saudi Arabia | 36 | 36 | 0 | CompaniesAll medicines |
| Spain | 35 | 17 | 18 | CompaniesAll medicines |
| Italy | 18 | 18 | 0 | CompaniesAll medicines |
| Romania | 18 | 0 | 18 | CompaniesAll medicines |
| United States | 10 | 10 | 0 | CompaniesAll medicines |
| Croatia | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of France, Serbia, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Contains Irish Public Sector Data licensed under Creative Commons Attribution 4.0 International (CC BY 4.0), Companies Registration Office; original dataset/API URL and company number, exact locator/source version and retrieval date; selected field normalization by Prognia. https://creativecommons.org/licenses/by/4.0/
Licence: Creative Commons Attribution
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.